MEDROL PILLS 4MG

Medrol /Medrol

Composition and release form

Medrol - tablets:

1 tab. contains methylprednisolone 4, 16 and 32 mg, excipients: Calcium stearate; corn starch; lactose; sucrose;

in a pack of 10, 14, 20, 30, 50 or 100 pcs.

pharmachologic effect

Medrol has a glucocorticoid effect.

Indications

Endocrine diseases:

- primary and secondary adrenal insufficiency (drugs of choice Hydrocortisone or Cortisone; if necessary, synthetic analogues can be used in combination with mineralocorticoids; adding mineralocorticoid is of particular importance in pediatric practice);

- congenital adrenal hyperplasia;

- chronic and subacute thyroiditis;

- hypercalcemia in malignant tumors.

Diseases of the musculoskeletal system (including rheumatic) (as an adjunctive therapy for a short time to remove from an acute condition or during exacerbation):

- psoriatic arthritis;

- rheumatoid arthritis, including juvenile rheumatoid arthritis (in some cases, low-dose maintenance therapy may be required);

- ankylosing spondylitis;

- acute and subacute bursitis;

- acute nonspecific tendosynovit;

- acute gouty arthritis;

- posttraumatic osteoarthritis;

- synovitis in osteoarthritis;

- epicondylitis.

Systemic diseases of the connective tissue (in the period of exacerbation or in some cases as maintenance therapy):

- acute rheumatic heart disease;

- Systemic lupus erythematosus;

- systemic dermatomyositis (polymyositis);

- rheumatic polymyalgia;

- giant cell arteritis.

Skin diseases:

- pemphigus;

- Herpetiformis bullous dermatitis;

- severe erythema multiforme (Stevens-Johnson syndrome);

- exfoliative dermatitis;

- mushroom mycosis;

- severe psoriasis;

- severe seborrheic dermatitis.

Allergic reactions (severe or disabling conditions in which conventional therapy is ineffective):

- seasonal or year-round allergic rhinitis;

- serum sickness;

- bronchial asthma;

- contact dermatitis;

- atopic dermatitis;

- hypersensitivity reactions to drugs.

Eye diseases (severe acute and chronic allergic and inflammatory processes with eye damage):

- allergic regional corneal ulcers;

- inflammation of the anterior segment of the eye;

- diffuse posterior uveitis and choroiditis;

- sympathetic ophthalmia;

- allergic conjunctivitis;

- keratitis;

- chorioretinitis;

- optic neuritis;

- iritis and iridocyclitis.

Respiratory Diseases:

- symptomatic sarcoidosis;

- Leffler syndrome, which is not amenable to therapy by other means;

- berylliosis;

- fulminant or disseminated pulmonary tuberculosis in combination with appropriate anti-tuberculosis Chemotherapy;

- aspiration pneumonitis.

Hematological diseases:

- idiopathic thrombocytopenic purpura in adults;

- secondary thrombocytopenia in adults;

- Acquired (autoimmune) hemolytic anemia;

- erythroblastopenia (erythrocyte anemia);

- Congenital (erythroid) hypoplastic anemia.

Oncological diseases (as palliative therapy):

- leukemia and lymphomas in adults;

- acute leukemia in children.

Edematous syndrome:

- to stimulate diuresis and achieve remission of proteinuria in patients with nephrotic syndrome without uremia, idiopathic type, or caused by systemic lupus erythematosus.

Diseases of the gastrointestinal tract (for removing a patient from a critical condition):

- ulcerative colitis;

- regional enteritis.

Diseases of the nervous system:

- exacerbations of multiple sclerosis;

- swelling of the brain due to a brain tumor.

Other indications for use:

- tuberculous meningitis with a subarachnoid block or with a threat of block (in combination with appropriate anti-tuberculosis chemotherapy);

- trichinosis with damage to the nervous system or myocardium;

- organ transplantation.

Contraindications

Hypersensitivity to the components of Medrol.

The drug should be used with caution in gastric ulcer and duodenal ulcer, esophagitis, gastritis, acute or latent peptic ulcer, intestinal anastomosis (in the immediate history), ulcerative colitis with the threat of perforation or abscess,diverticulitis; diabetes and predisposition to it; hyperlipidemia; myasthenia, osteoporosis, hypothyroidism, hyperthyroidism, acute psychosis, acute and subacute myocardial infarction, congestive heart failure, arterial hypertension, severe liver dysfunction (especially with concomitant hypoalbuminemia) or kidneys, in open-angle liver cancer (especially with concomitant hypoalbuminemia) or in kidney, in open-heart, with heart failure, in case of open-angle liver function (especially with concomitant hypoalbuminemia) or in kidney, in case of open-angle liver function (especially with concomitant hypoalbuminemia), measles, strongyloidosis, AIDS, HIV infection; with active and latent tuberculosis, severe bacterial or viral infectious diseases (increases the risk of developing superinfection, masks the symptoms of the disease), it is permissible to use the drug only against the background of specific therapy. For systemic fungal infections, use of the drug is not recommended.

Use during pregnancy and lactation

The use of Medrol during pregnancy is possible if the expected effect of therapy outweighs the potential risk to the fetus (adequate and strictly controlled safety studies have not been performed). Women of childbearing age must be warned of the potential risk to the fetus (corticosteroids pass through the placenta). Nursing women are advised to stop either breastfeeding or the use of drugs, especially in high doses (corticosteroids penetrate into breast milk and may inhibit the production of endogenous corticosteroids, inhibit growth and cause undesirable effects in the offspring).

Side effects

On the part of the endocrine system: Itsenko-Cushing syndrome, adrenal cortex atrophy, hypothalamic-pituitary insufficiency (especially during stressful situations such as illness, injury, surgery), reduced carbohydrate tolerance, steroid diabetes, increased insulin requirements or oral hypoglycemic Drug in patients with diabetes mellitus, glycosuria, menstrual disorders, hirsutism, impotence, growth retardation in children. On the side of metabolism: negative nitrogen balance, sodium retention and water, edema, loss of potassium, hypokalemic alkalosis, increased body weight. For the digestive tract: peptic ulcer with possible perforation and bleeding, nausea, vomiting, ulcerative esophagitis, pancreatitis, bloating. From the nervous system and sensory organs: headache, dizziness, increased intracranial pressure, brain pseudotumor, mental disorders, convulsions, increased intraocular pressure, exophthalmos. From the cardiovascular system and blood (hematopoiesis, hemostasis): arterial hypertension, stasis naya heart failure (in predisposed patients), arrhythmia, thrombophilia. There are reports of heart rhythm disturbances and / or the development of vascular insufficiency and / or cardiac arrest after rapid on / in the introduction of high doses of methylprednisolone sodium succinate (administration of more than 0.5 g in less than 10 minutes); during or after the administration of large doses of methylprednisolone sodium succinate, bradycardia was noted (the relationship with the rate and duration of administration has not been established). On the part of the musculoskeletal system: muscle weakness, steroid myopathy, decrease in muscle mass, osteoporosis (especially in women and children); ruptures of tendons, primarily Achilles; vertebral compression fractures, aseptic necrosis of the humeral head and femur, pathological fractures of the long bones. On the skin side: thinning and atrophy of the epidermis, dermis and subcutaneous tissue, deterioration of regeneration, slow healing of wounds, petechia, striae, steroid acne, pyoderma, candidiasis, hypo-and hyperpigmentation, ecchymosis, Allergic reactions: urticaria, anaphylactic shock, bronchospasm. Others: reduced resistance to infectious diseases; reactions at the injection site: burning, numbness, pain, paresthesia and infection at the injection site, hyper- or hypopigmentation, scar formation at the injection site; atrophy of the skin and subcutaneous tissue, sterile abscess.

Dosage and administration

Medrol is taken orally. The dose may vary and must be chosen individually depending on the nature of the disease and the patient's response to therapy. The initial dose of Medrol is from 4 to 48 mg / day, depending on the nature of the disease. With less severe diseases, usually lower doses are usually sufficient, although individual patients may require higher doses. High doses may be required for such diseases and conditions as multiple sclerosis (200 mg / day), brain edema (200-1000 mg / day) and organ transplantation (up to 7 mg / kg / day).If after a sufficient period of time a satisfactory clinical effect is not obtained, the drug should be discontinued and a different type of therapy prescribed to the patient.

For children, the dose of Medrol is determined by the doctor taking into account the mass or surface of the body. With adrenal insufficiency - 0.18 mg / kg or 3.33 mg / m2 / day in 3 doses, with other indications - 0.42-1.67 mg / kg or 12.5-50 mg / m2 / day in 3 doses.

Storage conditions and shelf life

In the dark place at a temperature of no higher than 20 ° C. Shelf life - 5 years.